Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement.

Donini LM, Busetto L, Bischoff SC, Cederholm T, Ballesteros-Pomar MD, Batsis JA, Bauer JM, Boirie Y, Cruz-Jentoft AJ, Dicker D, Frara S, Fruhbeck G, Genton L, Gepner Y, Giustina A, Gonzalez MC, Han HS, Heymsfield SB, Higashiguchi T, Laviano A, Lenzi A, Nyulasi I, Parrinello E, Poggiogalle E, Prado CM, Salvador J, Rolland Y, Santini F, Serlie MJ, Shi H, Sieber C, Siervo M, Vettor R, Villareal DT, Volkert D, Yu J, Zamboni M, Barazzoni R (2022)

Publication Type: Journal article

Publication year: 2022

Journal

Book Volume: 41

Pages Range: 990-1000

Journal Issue: 4

DOI: 10.1016/j.clnu.2021.11.014

Abstract

INTRODUCTION: Loss of skeletal muscle mass and function (sarcopenia) is common in individuals with obesity due to metabolic changes associated with a sedentary lifestyle, adipose tissue derangements, comorbidities (acute and chronic diseases), and during the ageing process. Co-existence of excess adiposity and low muscle mass/function is referred to as sarcopenic obesity (SO), a condition increasingly recognized for its clinical and functional features that negatively influence important patient-centred outcomes. Effective prevention and treatment strategies for SO are urgently needed, but efforts are hampered by the lack of an universally established SO Definition and diagnostic criteria. Resulting inconsistencies in the literature also negatively affect the ability to define prevalence as well as clinical relevance of SO for negative health outcomes. AIMS AND METHODS: The European Society for Clinical Nutrition and Metabolism (ESPEN) and the European Association for the Study of Obesity (EASO) launched an initiative to reach expert consensus on a Definition and diagnostic criteria for SO. The jointly appointed international expert panel proposes that SO is defined as the co-existence of excess adiposity and low muscle mass/function. The diagnosis of SO should be considered in at-risk individuals who screen positive for a co-occurring elevated body mass index or waist circumference, and markers of low skeletal muscle mass and function (risk factors, clinical symptoms, or validated questionnaires). Diagnostic procedures should initially include assessment of skeletal muscle function, followed by assessment of body composition where presence of excess adiposity and low skeletal muscle mass or related body compartments confirm the diagnosis of SO. Individuals with SO should be further stratified into Stage I in the absence of clinical complications, or Stage II if cases are associated with complications linked to altered body composition or skeletal muscle dysfunction. CONCLUSIONS: ESPEN and EASO, as well as the expert international panel, advocate that the proposed SO Definition and diagnostic criteria be implemented into routine clinical practice. The panel also encourages prospective studies in addition to secondary analysis of existing datasets, to study the predictive value, treatment efficacy, and clinical impact of this SO definition.

Authors with CRIS profile

Involved external institutions

Università degli studi "La Sapienza" Italy (IT) University of Padua / Universita degli Studi di Padova Italy (IT) Università Vita-Salute San Raffaele (UniSR) Italy (IT) Universidad de Navarra Spain (ES) Hospital Universitario Ramón y Cajal Spain (ES) Catholic University of Pelotas / Universidade Católica de Pelotas (UCPel) Brazil (BR) Capital University of Medical Sciences / 首都医科大学 China (CN) Tel Aviv University Israel (IL) Complejo Asistencial Universitario de León Spain (ES) Uppsala University Sweden (SE) Ruprecht-Karls-Universität Heidelberg Germany (DE) Geneva University Hospitals / Hôpitaux universitaires de Genève (HUG) Switzerland (CH) Centre Hospitalier Universitaire (CHU) de Toulouse France (FR) University of North Carolina at Chapel Hill United States (USA) (US) Amsterdam University Medical Centers (Amsterdam UMC) / Amsterdam Universitair Medische Centra Netherlands (NL) University of Clermont Auvergne France (FR) Fujita Health University Japan (JP) Houston Texas Medical Center United States (USA) (US) Monash University Australia (AU) Seoul National University (SNU) / 서울대학교 Korea, Republic of (KR) Pennington Biomedical Research Center United States (USA) (US) Clínica Universidad de Navarra Spain (ES) Peking Union Medical College / 北京协和医学院 China (CN) University of Nottingham United Kingdom (GB) Universität Hohenheim Germany (DE) University of Pisa / Università di Pisa (UniPi) Italy (IT) University of Alberta Canada (CA) University of Verona / Università degli Studi di Verona Italy (IT) Università degli Studi di Trieste Italy (IT)

How to cite

APA:

Donini, L.M., Busetto, L., Bischoff, S.C., Cederholm, T., Ballesteros-Pomar, M.D., Batsis, J.A.,... Barazzoni, R. (2022). Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Clinical Nutrition, 41(4), 990-1000. https://dx.doi.org/10.1016/j.clnu.2021.11.014

MLA:

Donini, Lorenzo M., et al. "Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement." Clinical Nutrition 41.4 (2022): 990-1000.

BibTeX: Download